Riggs Asset Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Riggs Asset Management’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-50	Closed	-$148	–	678
2024 Q2	$148	Hold	50	–	–	﹤0.01%	639
2024 Q1	$147	Hold	50	–	–	﹤0.01%	639
2023 Q4	$125	Hold	50	–	–	﹤0.01%	411
2023 Q3	$156	Hold	50	–	–	﹤0.01%	406
2023 Q2	$230	Hold	50	–	–	﹤0.01%	378
2023 Q1	$355	Hold	50	–	–	﹤0.01%	351
2022 Q4	$321	Hold	50	–	–	﹤0.01%	318
2022 Q3	$1K	Hold	50	–	–	﹤0.01%	308
2022 Q2	$1K	Hold	50	–	–	﹤0.01%	289
2022 Q1	$1K	Hold	50	–	–	﹤0.01%	304
2021 Q4	$2K	Hold	50	–	–	﹤0.01%	299
2021 Q3	$4K	Hold	50	–	–	﹤0.01%	277
2021 Q2	$6K	Hold	50	–	–	﹤0.01%	253
2021 Q1	$5K	Hold	50	–	–	﹤0.01%	237
2020 Q4	$2K	Buy	+50	New	+$1.83K	﹤0.01%	252
2020 Q3	–	Sell	-50	Closed	-$1K	–	223
2020 Q2	$1K	Hold	50	–	–	﹤0.01%	236
2020 Q1	$2K	Hold	50	–	–	﹤0.01%	230
2019 Q4	$2K	Sell	50 -100	-67%	-$3.61K	﹤0.01%	264
2019 Q3	$6K	Sell	150 -15	-9%	-$590	﹤0.01%	192
2019 Q2	$8K	Hold	165	–	–	﹤0.01%	189
2019 Q1	$13K	Buy	+165	New	+$10.6K	0.01%	168

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riggs Asset Management's IMDX Position: Q3 2024 in Review

Riggs Asset Management sold out of Insight Molecular Diagnostics (IMDX) in Q3 2024, closing a stake of 50 shares — an estimated $148 sold.

Riggs Asset Management first reported a position in IMDX in Q1 2019 and held it in 21 quarters. The position peaked at $13K in Q1 2019. 21 funds tracked by Wall St. Rank hold IMDX as of Q3 2024.

Riggs Asset Management reported no remaining Insight Molecular Diagnostics position as of Q3 2024 after selling out during the quarter.
Riggs Asset Management sold 50 Insight Molecular Diagnostics shares in Q3 2024, an estimated $148.
Riggs Asset Management first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 21 quarters.
Riggs Asset Management's Insight Molecular Diagnostics position peaked at $13K in Q1 2019.
21 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2024.

Based on Riggs Asset Management's 13F filing for Q3 2024, filed 24 Oct 2024.